📜 What This Document Is ✨

This document is an 8-K filing, which is a very important, mandatory filing used to announce major, unexpected events that happen after the company has already been publicly listed. Think of it like an urgent "Heads Up!" bulletin to investors.

In simple terms, Prelude Therapeutics is using this filing to finalize the details of a large, planned sale of its stock and related warrants. This type of document, known as an underwriting agreement, shows the deep legal promises and the precise money mechanics involved when raising a massive amount of capital from investment banks.

👉 The main takeaway is that Prelude is executing a significant capital raise by selling shares and warrants to major underwriters, Goldman Sachs & Co. LLC and Evercore Group L.L.C., at specific prices.

🏢 Who Is Prelude Therapeutics? 🧪

While this filing is highly focused on the logistics of a stock sale and does not provide an "About Us" summary, we know that Prelude Therapeutics Incorporated is a Delaware corporation. The company is raising capital through the sale of its voting common stock and pre-funded warrants.

👉 The immediate context for the reader is that Prelude is a company that is undergoing a major financial transaction, using the proceeds from this offering to fund its operations.

💰 Financial Highlights: The Deal Structure 💰

The heart of this filing is the agreement for Prelude to sell securities to the Underwriters (the big investment banks). The company is offering two types of assets: standard voting common stock and "pre-funded warrants."

• The Shares: The company commits to selling an aggregate of 18,018,014 shares of voting common stock.
• The Warrants: Alongside the shares, the company is selling pre-funded warrants to purchase up to 2,252,252 shares of voting common stock.

👉 Because the shares and warrants are being sold together in one package, the underwriting process dictates a specific pricing structure for both assets.

💲 Pricing and Purchase Mechanics 💵

The document details two levels of pricing: the negotiated Purchase Price and the publicly announced Offering Price. These are crucial for understanding the deal's value.

• The Negotiated Purchase Price: The underwriters agree to pay a purchase price of $4.1736 per Share and a separate price for the warrants.
• The Offering Price: When the securities are actually sold to the public, the initial offering prices are:
  • Shares: $4.44 per share.
  • Pre-Funded Warrants: $4.4399 per warrant.

👉 The difference between the negotiated Purchase Price and the Offering Price reflects the total size of the transaction and the structure used by the underwriters.

🗓️ The Timeline and Payment 📅

The filing sets clear dates and logistical steps for when the money changes hands, which is known as the "Closing Date."

• Closing Date: Payment for the securities is scheduled for April 21, 2026, or on the fifth business day after that date.
• Payment Method: Payment will be made via wire transfer to a designated bank account.
• Warrant Specifics: The underwriters must make payments for the Pre-Funded Warrants directly to Goldman Sachs & Co. LLC at $4.4399 per warrant.

👉 This strict payment schedule and mechanism ensure that the funds are received and available to the company on a specific timeline.

🤝 Who Are the Key Players? 🏦

The transaction involves several key parties responsible for facilitating the sale and guaranteeing the process.

• The Company: Prelude Therapeutics Incorporated (a Delaware corporation).
• The Underwriters: Goldman Sachs & Co. LLC and Evercore Group L.L.C. These are the investment banks managing and selling the securities.
• The Representatives: The collective group that works with the underwriters to manage the offering.
• Counsel & Accountants: The process is overseen by numerous legal firms (Morgan Lewis & Bockius LLP, Baker & Hostetler LLP, Morrison Foerster LLP, Cooley LLP) and independent public accounting firms, including Ernst & Young LLP.

👉 The involvement of major financial and legal firms adds layers of professional vetting, giving investors a measure of confidence in the transaction's completion.

📄 The Legal Promises (Representations and Warranties) 📜

This section is the legal core, where Prelude Therapeutics gives formal guarantees to the underwriters that everything about the company is true. It's essentially the company promising that all its homework is completed and accurate.

• Corporate Status: Prelude warrants that it is validly existing in good standing in Delaware, has corporate power, and is not subject to any existing legal impediments.
• Financial & Legal Cleanliness: The company guarantees it has no outstanding material liabilities and that all historical financial records are compliant with U.S. GAAP (Generally Accepted Accounting Principles).
• Intellectual Property (IP): Prelude assures the underwriters that it owns or has the right to use all necessary patents, copyrights, and know-how required for its business.
• Regulatory Compliance: The company guarantees compliance with major health care laws, including all rules from the FDA and other regulatory bodies.
• Ethics & Conduct: They confirm compliance with anti-corruption laws and regulations (like the Foreign Corrupt Practices Act) and have no dealings with sanctioned countries or entities.

🚧 Pre-Closing Conditions and Covenants 🚦

The agreement isn't final until several conditions are met. These are the "if/then" clauses that must be cleared before the money changes hands.

• Required Legal Opinions: The underwriters' ability to buy the shares depends on receiving favorable legal opinions and negative assurance letters from several major law firms (Morgan Lewis & Bockius LLP, Cooley LLP, etc.).
• Information Flow: The company promises to furnish all required documents (like the Registration Statement and Time of Sale Prospectus) to the underwriters without charge and promptly upon request.
• Restrictions (The "Restricted Period"): During the 60 days after the prospectus is released, the company promises not to sell, grant, or enter into certain financial agreements that could dilute the value of the stock.

👉 These stringent conditions protect the underwriters by ensuring that the company's operational status and legal standing haven't materially worsened since the initial drafts were written.

🌍 Regulatory Compliance and Controls ✅

Given that the company operates in a highly regulated industry (implied by the legal text), the filing dedicates large sections to compliance assurances.

• Health Care Laws: Prelude affirms that its operations comply with all applicable laws, including the Federal Food, Drug, and Cosmetic Act and HIPAA.
• Financial Reporting: The company confirms it maintains adequate internal accounting controls (a required process to ensure that recorded transactions are accurate).
• Data Security: They guarantee compliance with major privacy laws, including GDPR (EU) and HIPAA (US), and have implemented technical safeguards to protect data.

📅 Supporting Logistics and Follow-Up ℹ️

The filing includes numerous internal covenants detailing the ongoing operational support the company will provide throughout the sale process.

• Future Reporting: Prelude commits to providing an earnings statement covering at least twelve months beginning with the first fiscal quarter after the agreement date.
• Expense Coverage: The agreement also dictates that the company will cover the substantial costs associated with the sale, including legal fees, printing costs, and expenses related to the roadshow presentations.

🧠 The Analogy 🧭

Selling company stock and warrants is like buying a highly sought-after bundle deal on a hot property. The "shares" are the main deed to the house, and the "pre-funded warrants" are like prepaid vouchers that guarantee you the right to buy a small portion of the deed later, at a discount. The underwriters are the specialized real estate buyers who pool their money to make sure the deal closes, relying heavily on the seller's binding promises (the representations and warranties) that the property is truly ours and has no hidden legal issues.

🧩 Final Takeaway ✨

This 8-K is a highly detailed legal mechanism for Prelude to raise capital, confirming that the sale of 18,018,014 shares and 2,252,252 warrants at an offering price of $4.44/$4.4399 is dependent on the satisfaction of dozens of complex legal, regulatory, and financial assurances made by the company.